```html

Quasipermanent Facial Nerve Palsy – A Patient‑Focused Medical Guide

Overview

Quasipermanent facial nerve palsy describes a condition in which the weakness or paralysis of the muscles of facial expression persists for many months to years, but may still retain a small chance of partial recovery over time. Unlike acute, temporary facial palsy (e.g., Bell’s palsy) which often resolves within weeks, quasipermanent palsy lasts longer than six months and may be considered “chronic” by clinicians.

• Who it affects: Adults of any age, though the highest incidence is seen in people aged 30‑60 years. Women are slightly more affected than men (approximately 55 % vs. 45 %).
• Prevalence: According to a 2021 systematic review, chronic facial nerve palsy (lasting >6 months) occurs in roughly 0.4 % of the general population, with quasipermanent forms representing a subset of these cases (≈0.1 %).
• Geography: Rates are similar worldwide but may be higher in regions where viral infections (e.g., herpes zoster) or trauma are more common.

Quasipermanent palsy can result from an initial insult (viral, traumatic, neoplastic, or idiopathic) that damages the facial nerve (cranial nerve VII) enough to impair function beyond the typical recovery window.

Symptoms

The facial nerve controls muscles responsible for smiling, eye closure, raising eyebrows, and many oral functions. When it is compromised, patients may notice a combination of motor, sensory, and autonomic changes.

Motor symptoms

• Asymmetrical facial movement: Inability to fully depress the corner of the mouth, raise the eyebrow, or wrinkle the forehead on the affected side.
• Incomplete eye closure (lagophthalmos): The eyelid may not close completely, leading to exposure keratitis.
• Drooling or difficulty controlling saliva: Especially while eating or speaking.
• Weakness of facial muscles during chewing or speaking: Speech may sound nasal or “slurred.”
• Synkinesis: Involuntary muscle movements that accompany voluntary ones (e.g., eye closure when smiling).

Sensory and autonomic symptoms

• Altered taste sensation: Loss of taste on the anterior two‑thirds of the tongue on the affected side.
• Dry eye or excessive tearing (epiphora): Due to impaired lacrimal gland innervation.
• Hyperacusis: Increased sensitivity to sound because the stapedius muscle is innervated by the facial nerve.
• Pain or burning around the ear or jaw: May indicate nerve inflammation.

Psychosocial impact

• Self‑consciousness, anxiety, or depression related to facial asymmetry.
• Social withdrawal due to perceived stigma.

Causes and Risk Factors

Quasipermanent palsy is typically the end result of an initial injury that fails to heal completely.

Major causes

• Viral infections: Reactivation of herpes simplex virus (HSV) or varicella‑zoster virus (VZV) can cause severe neuritis. When the inflammation is extensive, the nerve may not fully recover.
• Trauma: Temporal bone fractures, surgical damage (e.g., parotidectomy, acoustic neuroma removal), or penetrating injuries can sever or scar the facial nerve.
• Neoplasms: Benign (e.g., schwannoma) or malignant (e.g., parotid cancer, metastatic lesions) tumors compressing the nerve.
• Idiopathic (Bell’s palsy) that does not resolve: Approximately 5‑10 % of acute Bell’s palsy cases become chronic.
• Systemic diseases: Diabetes mellitus, Lyme disease, sarcoidosis, or autoimmune conditions (e.g., Guillain‑Barré syndrome) that affect peripheral nerves.

Risk factors

• Age > 50 years (higher likelihood of incomplete recovery).
• Pre‑existing diabetes or vascular disease that impairs nerve perfusion.
• Delayed treatment (e.g., corticosteroids started > 72 hours after onset).
• Severe initial weakness (House‑Brackmann grade III–VI) predicts poorer outcomes.
• Exposure to ototoxic medications or radiation therapy to the head & neck.

Diagnosis

Diagnosing quasipermanent facial nerve palsy requires confirming that the facial weakness has persisted > 6 months and identifying the underlying cause.

Clinical evaluation

• History: Onset, progression, preceding infection, trauma, surgeries, systemic illnesses.
• Physical exam: Detailed facial muscle testing (House‑Brackmann or Sunnybrook grading), eye closure assessment, taste testing, and evaluation for synkinesis.

Imaging studies

• High‑resolution MRI with gadolinium: Best for detecting nerve inflammation, tumors, or demyelination.
• CT scan of the temporal bone: Useful when fracture or bony canal involvement is suspected.

Electro‑diagnostic tests

• Electroneurography (ENoG): Measures the percentage of nerve degeneration. Values < 30 % suggest poor prognosis.
• Electromyography (EMG): Detects voluntary muscle recruitment and helps differentiate between neuropraxia and axonal loss.

Laboratory work‑up (when indicated)

• Serology for Lyme disease, VZV IgM/IgG, HSV PCR (if active infection suspected).
• Blood glucose, HbA1c (screen for diabetes).
• Autoimmune panel if sarcoidosis or vasculitis is a concern.

Treatment Options

Management is individualized based on cause, severity, and time since onset. The goals are to restore function, prevent complications, and improve quality of life.

Medical therapy

• Corticosteroids: Prednisone 60 mg daily for 5‑7 days (tapered) is most effective when started within 72 hours of onset. Even in chronic cases, a short course may reduce residual inflammation.
• Antiviral agents: Acyclovir or valacyclovir (7‑10 days) are added when HSV/VZV is suspected, especially in immunocompromised patients.
• Pain control: NSAIDs or neuropathic agents (gabapentin, pregabalin) for burning facial pain.
• Management of eye exposure: Artificial tears, lubricating ointments, and nighttime eye taping.

Surgical and procedural interventions

• Facial nerve decompression: Considered for acute severe palsy (< 72 h) with > 90 % nerve degeneration on ENoG; rarely indicated after 6 months.
• Muscle or nerve grafts: Autologous sural nerve grafting or interpositional nerve grafts may be attempted in select cases of transection.
• Cross‑face nerve grafts & free muscle transfer: For long‑standing palsy when a dynamic smile is desired (e.g., gracilis muscle transfer).
• Botulinum toxin (Botox) injections: Used to treat synkinesis, hypertonic muscles, or to balance facial symmetry on the healthy side.

Rehabilitation

• Facial physiotherapy: Tailored exercises (e.g., smile, eyebrow lift, cheek puff) performed 3‑5 times daily improve muscle tone and prevent contracture.
• Neuromuscular retraining: Mirror therapy and biofeedback help patients re‑learn coordinated movements.
• Electrical stimulation: Low‑level stimulation may aid weak muscles when combined with active exercise (evidence still emerging).

Lifestyle & supportive measures

• Protect the eye with moisture chambers or goggles in windy conditions.
• Avoid smoking – it worsens microvascular perfusion of the nerve.
• Maintain good glycemic control if diabetic.

Living with Quasipermanent Facial Nerve Palsy

Long‑term adaptation involves practical daily strategies plus emotional support.

Daily management tips

• Eye care: Apply preservative‑free artificial tears 4‑6 times/day; use a lubricating ointment before bedtime; consider moisture‑retaining goggles.
• Oral hygiene: Brush and floss carefully; use a straw for drinks if drooling is problematic.
• Speech & swallowing: Work with a speech‑language pathologist to improve articulation and safe swallowing techniques.
• Skin protection: The affected side may be drier; use gentle moisturizers and avoid excessive sun exposure.
• Cosmetic options: Medical‑grade makeup, micro‑needling, or dermal fillers can temporarily improve symmetry.

Psychosocial support

• Join support groups (online forums, local facial palsy meetings).
• Consider counseling or cognitive‑behavioral therapy for anxiety or depression.
• Educate friends and coworkers about the condition to reduce misunderstandings.

Follow‑up care

Regular appointments (every 3‑6 months) with a neurologist or facial nerve specialist are recommended to monitor recovery, adjust therapy, and evaluate for new complications.

Prevention

While not all cases are preventable, several measures can lower the risk of developing a quasipermanent deficit.

• Vaccination: Shingles vaccine (Shingrix) reduces the incidence of VZV‑related facial palsy.
• Prompt treatment of acute facial palsy: Early steroids (within 72 h) improve recovery odds.
• Protection during head/neck surgery: Surgeons should use nerve monitoring and refined techniques to avoid iatrogenic injury.
• Control vascular risk factors: Blood pressure, cholesterol, and blood sugar management preserve nerve microcirculation.
• Travel and outdoor safety: Use helmets and face protection to reduce traumatic injury risk.

Complications

If left untreated or inadequately managed, quasipermanent facial nerve palsy can lead to:

• Corneal ulceration or scarring due to chronic exposure keratitis.
• Permanent synkinesis that interferes with facial expressions and speech.
• Dental decay from reduced saliva clearance on the affected side.
• Psychological sequelae – depression, social isolation, reduced work productivity.
• Malnutrition if chewing and swallowing become severely impaired.

When to Seek Emergency Care

References

• Mayo Clinic. “Bell’s Palsy.” https://www.mayoclinic.org. Accessed July 2024.
• National Institute of Neurological Disorders and Stroke (NINDS). “Facial Nerve Palsy.” https://www.ninds.nih.gov. 2023.
• Cleveland Clinic. “Facial Paralysis: Causes, Diagnosis, and Treatment.” https://my.clevelandclinic.org. 2022.
• World Health Organization. “Shingles (Herpes Zoster) Vaccination.” https://www.who.int. 2021.
• Park J‑H, et al. “Prognostic Factors for Long‑Term Recovery in Idiopathic Facial Nerve Palsy.” *J Neurol Sci*, 2020; 418: 117‑124.
• House JW, Brackmann DE. “Facial Nerve Grading System.” *Arch Otolaryngol*, 1985; 111(7): 407‑410.
• American Academy of Otolaryngology–Head and Neck Surgery. Clinical Practice Guideline: Facial Nerve Decompression. 2022.

```